Download MendeleyBBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3K alpha interaction.
Simanshu, D.K., Xu, R., Stice, J.P., Czyzyk, D.J., Feng, S., Denson, J.P., Riegler, E., Yang, Y., Zhang, C., Donovan, S., Smith, B.P., Abreu-Blanco, M., Chen, M., Feng, C., Fu, L., Rabara, D., Young, L.C., Dyba, M., Yan, W., Lin, K., Ghorbanpoorvalukolaie, S., Larsen, E.K., Malik, W., Champagne, A., Parker, K., Ju, J.H., Jeknic, S., Esposito, D., Turner, D.M., Lightstone, F.C., Wang, B., Wehn, P.M., Wang, K., Stephen, A.G., Maciag, A.E., Hata, A.N., Sinkevicius, K.W., Nissley, D.V., Wallace, E.M., McCormick, F., Beltran, P.J.(2025) Science 389: 409-415
- PubMed: 40504949 Search on PubMed
- DOI: https://doi.org/10.1126/science.adq2004
- Primary Citation Related Structures:
9B4U - PubMed Abstract:
BBO-10203 is an orally available drug that covalently and specifically binds to the RAS-binding domain of phosphoinositide 3-kinase α (PI3Kα), preventing its activation by HRAS, NRAS, and KRAS. It inhibited PI3Kα activation in tumors with oncogenic mutations in KRAS or PIK3CA , and in tumors with human epidermal growth factor receptor 2 (HER2) amplification or overexpression. In preclinical models, BBO-10203 caused significant tumor growth inhibition across multiple tumor types and showed enhanced efficacy in combination with inhibitors of cyclin-dependent kinase 4/6 (CDK4/6), estrogen receptor (ER), HER2 and KRAS-G12C mutant, including in tumors harboring mutations in Kelch-like ECH-associated protein 1 (KEAP1) and Serine/Threonine Kinase 11 (STK11). Notably, these antitumor effects occurred without inducing hyperglycemia, as insulin signaling does not depend on RAS-mediated PI3Kα activation to promote glucose uptake.
- NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Organizational Affiliation:
